BioWorld

May 20, 2005

View Archived Issues

Gemin X Can Take Lead Drug Through Phase II With $65M

Raising $65.2 million in its largest financing to date, Gemin X Biotechnologies Inc. plans to advance its lead oncology candidate through Phase II studies. (BioWorld Today) Read More

Enanta In-Licenses Chiron's HCV Protease Inhibitor Group

Read More

South Korean Team Makes Patient-Specific Stem Cells

Read More

House Vote Expected Soon On Bipartisan Stem Cell Bill

Read More

Other News To Note

Read More

Appointments And Advancements

Read More